Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 17/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040568 | 1.00 | PTPN11 (0.61) | PTPN11KCNH2EGFRSCN9ADRD2 | |
| SCHEMBL30040744 | 0.82 | PTPN11 (0.69) | PTPN11KCNH2EGFRSCN9ADRD2 | |
| SCHEMBL24033795 | 0.82 | PTPN11 (0.69) | PTPN11KCNH2EGFRSCN9ADRD2 | |
| SCHEMBL24033719 | 0.80 | PTPN11 (0.66) | PTPN11KCNH2EGFRSCN9A | |
| SCHEMBL25514319 | 0.78 | PTPN11 (0.84) | PTPN11KCNH2EGFR | |
| SCHEMBL24033797 | 0.78 | PTPN11 (0.60) | PTPN11KCNH2EGFRDRD2DRD3 | |
| SCHEMBL30041299 | 0.78 | PTPN11 (0.60) | PTPN11KCNH2EGFRDRD2DRD3 | |
| SCHEMBL24033796 | 0.76 | PTPN11 (0.69) | PTPN11KCNH2EGFRSCN9A | |
| SCHEMBL30040098 | 0.76 | PTPN11 (0.69) | PTPN11KCNH2EGFRSCN9A | |
| SCHEMBL19785043 | 0.76 | PTPN11 (1.00) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115353509-B | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-115353509-A | Aza-containing aromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-111295374-B | Aza-containing aromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| CN-111295374-A | Aza-containing aromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | PTPN11, PTPN1, PTPN7 | PTPN11 1/4885KCNH2 4613/4885EGFR 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.